Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry

Pigment Cell and Melanoma Research

Volumn 25, Issue 5, 2012, Pages 630-638

  Liu, Ruifang ^a,b   Cao, Zhifei ^a,b   Tu, Jian ^a,b   Pan, Yanyan ^a,b   Shang, Bingxue ^a,b   Zhang, Gaochuan ^a,b   Bao, Meimei ^a,b   Zhang, Shasha ^a,b   Yang, Ping ^a,b   Zhou, Quansheng ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b National Clinical Research Center for Hematological Diseases   (China)

Author keywords

Angiogenesis; Lycorine hydrochloride; Melanoma; Tumor; Vasculogenic mimicry; VE cadherin

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; LUCIFERASE; LYCORINE HYDROCHLORIDE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTATIC MELANOMA; MOUSE; NONHUMAN; TUMOR BLOOD FLOW;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; ANTIGENS, CD; CADHERINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHENANTHRIDINES; PROMOTER REGIONS, GENETIC; SKIN NEOPLASMS;

EID: 84865545950     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.01036.x     Document Type: Article

References (36)

1. Alghisi, G.C., Ponsonnet, L., and Ruegg, C. (2009). The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS ONE 4, e4449.
2. Balch, C.M., Gershenwald, J.E., Soong, S.J. et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
3. Bhat, Y.M., Furth, E.E., Brensinger, C.M., and Ginsberg, G.G. (2009). Endoscopic resection with ligation using a multi-band mucosectomy system in Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma. Therap. Adv. Gastroenterol. 2, 323-330.
4. Camacho, L.H., Antonia, S., Sosman, J. et al. (2009). Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075-1081.
5. Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307.
6. Dejana, E., and Giampietro, C. (2012). Vascular endothelial-cadherin and vascular stability. Curr. Opin. Hematol. 19, 218-223.
7. Dejana, E., Orsenigo, F., and Lampugnani, M.G. (2008). The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 121, 2115-2122.
8. Ebos, J.M., and Kerbel, R.S. (2011). Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221.
9. Eggermont, A.M., and Robert, C. (2011). New drugs in melanoma: it's a whole new world. Eur. J. Cancer 47, 2150-2157.
10. Eggermont, A.M., and Robert, C. (2012). Melanoma in 2011: a new paradigm tumor for drug development. Nat. Rev. Clin. Oncol. 9, 74-76.
11. Flaherty, K.T., and Fisher, D.E. (2011). New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin. Cancer Res. 17, 4922-4928.
12. Gavard, J. (2009). Breaking the VE-cadherin bonds. FEBS Lett. 583, 1-6.
13. Helfrich, I., and Schadendorf, D. (2011). Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance. Mol. Oncol. 5, 137-149.
14. Hersey, P., Bastholt, L., Chiarion-Sileni, V. et al. (2009). Small molecules and targeted therapies in distant metastatic disease. Ann. Oncol. 20(Suppl 6), vi35-vi40.
15. Hess, A.R., Margaryan, N.V., Seftor, E.A., and Hendrix, M.J. (2007). Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev. Dyn. 236, 3283-3296.
16. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
17. Ingrassia, L., Lefranc, F., Mathieu, V., Darro, F., and Kiss, R. (2008). Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agents. Transl. Oncol. 1, 1-13.
18. Lamoral-Theys, D., Andolfi, A., Van Goietsenoven, G. et al. (2009). Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J. Med. Chem. 52, 6244-6256.
19. Lamoral-Theys, D., Decaestecker, C., Mathieu, V., Dubois, J., Kornienko, A., Kiss, R., Evidente, A., and Pottier, L. (2010). Lycorine and its derivatives for anticancer drug design. Mini Rev. Med. Chem. 10, 41-50.
20. Le, G.A., Dwyer, J., and Gavard, J. (2011). Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol. Cell 103, 593-605.
21. Liu, X.S., Jiang, J., Jiao, X.Y., Wu, Y.E., Lin, J.H., and Cai, Y.M. (2009). Lycorine induces apoptosis and down-regulation of Mcl-1 in human leukemia cells. Cancer Lett. 274, 16-24.
22. Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe'er, J., Trent, J.M., Meltzer, P.S., and Hendrix, M.J. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752.
23. Marneros, A.G. (2009). Tumor angiogenesis in melanoma. Hematol. Oncol. Clin. North Am. 23, 431-446, vii-viii.
24. May, C., Doody, J.F., Abdullah, R. et al. (2005). Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood 105, 4337-4344.
25. Mourad-Zeidan, A.A., Melnikova, V.O., Wang, H., Raz, A., and Bar-Eli, M. (2008). Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am. J. Pathol. 173, 1839-1852.
26. Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887.
27. Prandini, M.H., Dreher, I., Bouillot, S., Benkerri, S., Moll, T., and Huber, P. (2005). The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene 24, 2992-3001.
28. Qian, L.W., Greene, W., Ye, F., and Gao, S.J. (2008). Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin. J. Virol. 82, 11902-11912.
29. van der Schaft, D.W., Seftor, R.E., Seftor, E.A., Hess, A.R., Gruman, L.M., Kirschmann, D.A., Yokoyama, Y., Griffioen, A.W., and Hendrix, M.J. (2004). Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J. Natl Cancer Inst. 96, 1473-1477.
30. Silverman, R.H., Halloum, A., Zhou, A., Dong, B., Al-Zoghaibi, F., Kushner, D., Zhou, Q., Zhao, J., Wiedmer, T., and Sims, P.J. (2002). Suppression of ovarian carcinoma cell growth in vivo by the interferon-inducible plasma membrane protein, phospholipid scramblase 1. Cancer Res. 62, 397-402.
31. Van Cutsem, E., Lambrechts, D., Prenen, H., Jain, R.K., and Carmeliet, P. (2011). Lessons from the adjuvant bevacizumab trial on colon cancer: what next. J. Clin. Oncol. 29, 1-4.
32. Van Goietsenoven, G., Andolfi, A., Lallemand, B. et al. (2010). Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. J. Nat. Prod. 73, 1223-1227.
33. Vestweber, D. (2008). VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler. Thromb. Vasc. Biol. 28, 223-232.
34. Zhao, Z., Yao, Y., Ding, Z. et al. (2011). Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin. Vaccine 29, 4218-4224.
35. Zhou, Q., Kiosses, W.B., Liu, J., and Schimmel, P. (2008). Tumor endothelial cell tube formation model for determining anti-angiogenic activity of a tRNA synthetase cytokine. Methods 44, 190-195.
36. Zhou, Q., Kapoor, M., Guo, M. et al. (2010). Orthogonal use of a human tRNA synthetase active site to achieve multifunctionality. Nat. Struct. Mol. Biol. 17, 57-61.